Video

LUGPA 2022: Dr. Shore on the significance of genetic testing in prostate cancer

Author(s):

Urology Times staff
Conference|LUGPA Annual Meeting

“There’s a lot of clinical utility to genetic testing, and there are familial implications and clinical trial implications,” explains Neal Shore, MD.

Neal Shore, MD, explains how genetic testing has become an essential component of the treatment paradigm for patients with prostate cancer. Shore is co-chairing the CME program at the 2022 LUGPA Annual Meeting, which will include a session on genetic testing. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).

Related Videos
Related Content
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
November 18th 2024

Expert robotic surgeon discusses da Vinci 5, advances in urologic surgery

Ronney Abaza, MD, FACS
"It's actually a very exciting time to be a robotic surgeon," says Ronney Abaza, MD, FACS.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 16th 2024

Expert discusses current trials in bladder cancer to watch for

Jason M. Hafron, MD, CMO
"Bladder cancer is exploding. [It] is exciting, it's changing, and we're just at the start of this," says Jason M. Hafron, MD, CMO.
Prostate cancer 3D illustration | Image Credit: © Dr_Microbe - stock.adobe.com
November 16th 2024

Focal therapy’s future in prostate cancer is bright, says Arvin George, MD

Arvin George, MD
"When we look at focal therapy in general, the better we're able to see, localize, identify and risk stratify prostate cancers, the better we're able to treat them and offer more personalized and focal treatments," says Arvin George, MD.
Blur image of hospital | Image Credit: © jakkapan - stock.adobe.com
November 15th 2024

Gautam Jayram, MD, on the top 5 things to know in bladder and kidney cancer

Gautam Jayram, MD
"We...talked a little bit about BCG-unresponsive disease, which is a really hot topic; a lot of trials and a lot of data are coming there," says Gautam Jayram, MD.
Prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
November 15th 2024

Scott Eggener, MD, on a pragmatic approach to prostate cancer innovations

Benjamin P. Saylor
“You have to be balanced in what to embrace vs what not. It is easy to be wowed by new things," said Scott Eggener, MD.
© 2024 MJH Life Sciences

All rights reserved.